Skip to main content
Signal8
Launch Terminal

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Scholar Rock Holding Corporation logo

Scholar Rock Holding Corporation

NASDAQ:SRRKHealthcare
-0.63%$43.90
AH$43.50-0.91%vs close
Mkt Cap$5.35B
Float109.19M
O/S121.79M
Vol
$ Vol
RVOL
Inst Own-
SI20.3%
Earnings
Dilution
Scholar Rock Holding Corporation logoNASDAQ:SRRK$43.90-0.63%
Phase Distribution
9 lead-sponsored trials·4 active·4 completed
Phase 12
Phase 24
Phase 32
Not applicable1
(1 more as collaborator)
Status Overview
Recruiting3
Active, not recruiting1
Completed4
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

    Apitegromab, Placebo

    Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 +8

    Enrollment
    188
    Start
    Apr 2022
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT05156320
  • Phase 3
    Active, not recruiting

    Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

    Apitegromab

    Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 +8

    Enrollment
    238
    Start
    Apr 2023
    Primary Completion
    Nov 2026est.
    Completion
    May 2029est.
    NCT05626855
  • Phase 2
    Completed

    An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

    SRK-015

    Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 +7

    Enrollment
    58
    Start
    Apr 2019
    Primary Completion
    Jan 2021
    Completion
    Feb 2024
    NCT03921528
  • Phase 2
    Completed

    Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

    Apitegromab, Placebo

    Overweight and Obesity

    Enrollment
    102
    Start
    May 2024
    Primary Completion
    Mar 2025
    Completion
    Jun 2025
    NCT06445075
  • Phase 2
    Recruiting

    A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

    Apitegromab, Nusinersen

    Spinal Muscular Atrophy, SMA +4

    Enrollment
    52
    Start
    Sep 2025
    Primary Completion
    Nov 2028est.
    Completion
    Mar 2029est.
    NCT07047144
  • Phase 2
    Recruiting

    Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

    Apitegromab, Placebo

    Facioscapulohumeral Muscular Dystrophy, FSHD

    Enrollment
    60
    Start
    Jul 2026
    Primary Completion
    Jun 2028est.
    Completion
    Dec 2028est.
    NCT07435129
  • Phase 1
    Completed

    SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

    SRK-181, anti-PD-(L)1 antibody therapy

    Cancer

    Enrollment
    112
    Start
    Apr 2020
    Primary Completion
    Apr 2025
    Completion
    Apr 2025
    NCT04291079
  • Phase 1
    Recruiting

    A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults

    Placebo, SRK-439

    Healthy

    Enrollment
    76
    Start
    Nov 2025
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2027est.
    NCT07444294
  • Expanded access
    No longer available

    EAP of Apitegromab for Patients With Spinal Muscular Atrophy

    Apitegromab

    SMA

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06877689
Search ClinicalTrials.gov for “Scholar Rock Holding”